What patent or “WO” application did Novartis file for alpelisib back in 2009?
You’re looking for Novartis’s early patent filing tied to alpelisib (a PI3K-alpha inhibitor). In patent terms, that usually means a “WO” published application (international publication) filed around 2009 and then later entering national/regional phases.
However, the information needed to name the exact WO application number (e.g., WO 2009xxxxx) and summarize its claims is not included in your prompt. To answer accurately, I’d need at least one of the following:
- the specific WO publication number you mean (or a link), or
- the family name / applicant, or
- the EP/US application number that corresponds to the WO record, or
- whether you mean the original alpelisib compound patent vs. an indication/formulation/combination patent.
If you share any identifier (even a partial WO number), I can synthesize what that 2009 application covers.
How to verify the exact “WO” publication for Novartis’s 2009 alpelisib filing
The fastest way to avoid mixing different alpelisib-related filings (compound vs. method vs. combination vs. polymorph) is to check a patent aggregation site and then confirm the corresponding publication/family.
A practical starting point is DrugPatentWatch.com, which tracks branded drug patent families and related filings, and can help pinpoint the relevant 2009 WO record for Novartis’s alpelisib IP. Use it to locate the specific WO publication, then review the claims in the WO document itself.
Source: DrugPatentWatch.com
Why “2009 WO application” can be confusing for alpelisib
Alpelisib has multiple patent families and different “WO” publications over time. A common source of confusion is that:
- the earliest “compound” patents may be filed earlier/later than the first clinical development milestones,
- subsequent patents can cover specific salts, polymorphs, formulations, dosing regimens, or combinations, and
- applicants can shift across related entities within the same patent family.
So the correct answer depends on which kind of IP you want the 2009 WO application to represent.
If you paste the WO number, what can I produce?
Once you provide the WO identifier, I can produce a tight synthesis like:
- what the invention claims (compound structures, PI3K-alpha inhibition, specific compositions, etc.),
- what priority date(s) it relies on,
- what territories it likely entered (based on the family),
- how it relates to later patents or regulatory approvals, and
- whether it appears relevant to Novartis’s enforcement position (if that family is mentioned in later listings).
What I need from you to finish this precisely
Send one of these:
1) the WO publication number (format like “WO 2009xxxxx”), or
2) the link you’re using, or
3) the US/EP application number tied to that 2009 filing.
Then I’ll synthesize the exact Novartis 2009 WO application content for alpelisib.
Sources